Paliperidone: all 134 studies that test it

Page 1 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• A Bioequivalence Study of PP3M in Patients With SchizophreniaRecruitingNCT07493551Not applicable
• Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh StudyNot yet recruitingNCT07153835Phase 4
• Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in SchizophreniaNot yet recruitingNCT07075237Phase 4
• Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology AnalysisNot yet recruitingNCT06060886Phase 4
• "Extended" (Alternate Day) Antipsychotic DosingRecruitingNCT04478838Phase 4
• A Study of Paliperidone Palmitate 6-Month FormulationCompletedNCT04072575Phase 3Results posted
• A Study of Paliperidone Palmitate 6-Month FormulationCompletedNCT03345342Phase 3Results posted
• A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass SpectrometryTerminatedNCT02462473Phase 2Results posted
• A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or SchizophreniformCompletedNCT02431702Phase 3Results posted
• Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With SchizophreniaCompletedNCT01724359Phase 4Results posted
• Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With SchizophreniaCompletedNCT01662648Phase 3Results posted
• An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With SchizophreniaCompletedNCT01662310Phase 3Results posted
• A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With SchizophreniaCompletedNCT01606254Phase 2Results posted
• A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With SchizophreniaCompletedNCT01606228Phase 3Results posted
• Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)CompletedNCT01577186Phase 4Results posted
• A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With SchizophreniaCompletedNCT01577160Phase 4Results posted
• A Long-Term Study of JNS007ER in Patients With SchizophreniaCompletedNCT01561898Phase 3Results posted
• A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With SchizophreniaCompletedNCT01541371Phase 3Results posted
• A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With SchizophreniaCompletedNCT01529515Phase 3Results posted
• Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With SchizophreniaCompletedNCT01515423Phase 3Results posted
• Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia ParticipantsCompletedNCT01387542Phase 4Results posted
• Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 YearsCompletedNCT01362439Phase 4Results posted
• An Efficacy and Safety Study of Paliperidone Palmitate in Participants With SchizophreniaCompletedNCT01299389Phase 3Results posted
• Different Safety Profile of Risperidone and Paliperidone Extended-releaseCompletedNCT01284959Phase 4Results posted
• A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective DisorderCompletedNCT01193153Phase 3Results posted
• 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and IncarceratedCompletedNCT01157351Phase 4Results posted
• A Comparison of Long-acting Injectable Medications for SchizophreniaCompletedNCT01136772Phase 4Results posted
• Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic RegulationCompletedNCT01134731Phase 4Results posted
• Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral AntipsychoticsCompletedNCT01081769Phase 3Results posted
• A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With RisperidoneCompletedNCT01010776Phase 4Results posted
• An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With SchizophreniaCompletedNCT01009047Phase 3Results posted
• 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 YearsTerminatedNCT00946985Phase 4Results posted
• A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy ControlsTerminatedNCT00934635Phase 4Results posted
• Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic ParticipantsCompletedNCT00784238Phase 4Results posted
• Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic ParticipantsCompletedNCT00761605Phase 4Results posted
• Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic RemissionCompletedNCT00761579Phase 4Results posted
• PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute SchizophreniaCompletedNCT00761189Phase 4Results posted
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With SchizophreniaCompletedNCT00757705Phase 4Results posted
• A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With SchizophreniaCompletedNCT00645099Phase 3Results posted
• Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive DisorderCompletedNCT00632229Phase 2Results posted
• A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With SchizophreniaCompletedNCT00604279Phase 3Results posted
• Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar DisorderTerminatedNCT00592358Phase 4Results posted
• Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With SchizophreniaCompletedNCT00590577Phase 3Results posted
• Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaCompletedNCT00589914Phase 3Results posted
• An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With SchizophreniaCompletedNCT00566631Phase 3Results posted
• Study of Paliperidone ER in Adolescents and Young Adults With AutismCompletedNCT00549562Phase 3Results posted
• Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to PaliperidoneCompletedNCT00535132Phase 4Results posted
• An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With SchizophreniaCompletedNCT00524043Phase 4Results posted
• A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent PatientsCompletedNCT00518323Phase 3Results posted
• A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I DisorderCompletedNCT00490971Phase 3Results posted
• Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.CompletedNCT00488319Phase 3Results posted
• An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With SchizophreniaCompletedNCT00473434Phase 3Results posted
• Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.CompletedNCT00412373Phase 3Results posted
• Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.CompletedNCT00397033Phase 3Results posted
• A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With SchizophreniaCompletedNCT00396565Phase 3Results posted
• Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With SchizophreniaCompletedNCT07268430Not applicable
• Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT05321602Phase 1
• A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare SettingsCompletedNCT04940039Phase 4
• Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate TreatmentCompletedNCT04754750Phase 1/2
• Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia PatientsCompletedNCT04572685Phase 1
• Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical AntipsychoticsCompletedNCT03730857Phase 1
• A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare FacilitiesCompletedNCT03713658Phase 4
• Substance Misuse To Psychosis for StimulantsCompletedNCT03485417Phase 2/3
• A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This TreatmentCompletedNCT03425552Phase 1/2
• The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With SchizophreniaStatus unknownNCT03080194Phase 4
• Long-acting Paliperidone Palmitate Injection and Olanzapine for SchizophreniaCompletedNCT02918825Not applicable
• A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month FormulationCompletedNCT02713282Phase 3
• Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or RisperidoneCompletedNCT02634463Phase 1
• An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS DependenceStatus unknownNCT02541513Phase 3
• A Pharmacokinetic Study of Paliperidone ERStatus unknownNCT02433717Phase 4
• Pharmacovigilance in Gerontopsychiatric PatientsTerminatedNCT02374567Phase 3
• Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsCompletedNCT02307396Phase 4
• European Long-acting Antipsychotics in Schizophrenia TrialCompletedNCT02146547Phase 4
• Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric ParticipantsCompletedNCT02087579Phase 1
• Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ERCompletedNCT02075528Phase 4
• A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With SchizophreniaCompletedNCT01947803Phase 4
• A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With SchizophreniaCompletedNCT01942382Phase 1
• The Effect of Paliperidone Palmitate in SchizophreniaCompletedNCT01860781Phase 4
• An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine DependenceCompletedNCT01825928Not applicable
• A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated PsychosisCompletedNCT01822730Phase 4
• A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral AntipsychoticsCompletedNCT01685931Phase 4
• A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone PalmitateCompletedNCT01682161Phase 4
• A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With SchizophreniaTerminatedNCT01670071Phase 4
• A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five AntipsychoticsCompletedNCT01607762Phase 1
• Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot StudyWithdrawnNCT01584466Not applicable
• A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute SchizophreniaCompletedNCT01527305Phase 4
• Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode SchizophreniaCompletedNCT01451736Phase 4
• Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone PalmitateCompletedNCT01448720Phase 3
• Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia PatientsCompletedNCT01399450Phase 4
• Paliperidone Palmitate Flexible Dosing in SchizophreniaCompletedNCT01281527Phase 3
• A Study of Paliperidone Palmitate in Japanese Patients With SchizophreniaCompletedNCT01258920Phase 3
• Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by AlcoholismWithdrawnNCT01211704Phase 4
• Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric HospitalWithdrawnNCT01193166Phase 4
• Efficacy and Safety of Paliperidone ER in First Episode PsychosisCompletedNCT01157585Phase 4
• A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone PalmitateCompletedNCT01110317Phase 1
• A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective DisorderCompletedNCT01094249Phase 1
• A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy MenCompletedNCT01060228Phase 1
• A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With SchizophreniaCompletedNCT01051531Phase 3
• IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute AgitationCompletedNCT01050478Phase 4
• Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) ScanningStatus unknownNCT00937261Phase 4

← Paliperidone overview